RESUMEN
Resumen: OBJETIVO Evaluar la sensibilidad y valores predictivos de BAAR-Ziehl-Neelsen y GeneXpert (MTB/RIF) en muestras respiratorias y no respiratorias en población general y con VIH. MATERIAL Y MÉTODO Estudio clínico abierto, sin distribución al azar, prospectivo, descriptivo y observacional efectuado de mayo de 2016 a enero de 2017. Los criterios de inclusión fueron: pacientes con datos clínicos epidemiológicos radiológicos que sugirieran tuberculosis en la evaluación diagnóstica o riesgo de padecerla. Se hizo toma simultánea de expectoración o muestra extrapulmonar para determinación de BAAR-Ziehl-Neelsen, GeneXpert MTB y cultivo; se utilizó como patrón de referencia el cultivo. RESULTADOS Se incluyeron en el estudio 120 pacientes, 88 (73.3%) hombres. La justificación de la realización de la prueba fue enfermedad aguda grave 76 (63.3%), el factor de riesgo de mayor prevalencia fue el VIH-SIDA 54 (45.5%). El mayor porcentaje correspondió a la forma respiratoria (n = 75, 62.5%). El total de las muestras (n = 89, 74.2%) fueron negativas respecto a BAAR en contraste con GeneXpert y cultivo, que fueron positivos en 94 casos (78.3%). CONCLUSIONES Los indicadores estables evaluados en la prueba GeneXpert mostraron que es una prueba útil, sobre todo en muestras extrapulmonares de pacientes con VIH-SIDA.
Abstract: OBJECTIVE To assess the sensitivity and predictive values of BAAR Ziehl-Neelsen and GeneXpert (MTB/RIF) for respiratory and non-respiratory samples in the general population and HIV-patients. MATERIAL AND METHOD A clinical open, not-random, prospective, descriptive and observational study was done from May 2016 to January 2017. Inclusion criteria were: Patients with radiological, clinical and epidemiological data that suggested tuberculosis within the diagnostic evaluation or risk of having it. Simultaneous sputum or extrapulmonary sample was taken for determination of Ziehl-Neelsen, GeneXpert MTB and culture; the crop was used as a gold standard. RESULTS There were included 120 patients, 88 (73.3%) men; the justification for performing the test was severe acute disease (n = 76, 63.3%), the risk factor with the highest prevalence was HIV-AIDS (n = 54, 45.5%) The highest percentage was respiratory (n = 75, 62.5%). The total of samples 89 (74.2%) were negative with respect to BAAR in contrast to GeneXpert and culture, which reported positive in 94 (78.3%). CONCLUSIONS The stable indicators evaluated in the GeneXpert test showed that it is a useful test especially in extralung samples of patients with HIV-AIDS.
RESUMEN
BACKGROUND: Frequency of adrenal insufficiency in patients with tuberculosis varies from 0 to 58%; however, all published series excluded severely ill patients. Our objective was to investigate adrenal insufficiency with the low-dose cosyntropin test in patients with severe active tuberculosis. METHOD: From two large university affiliated hospitals, 18 patients with tuberculosis and criteria of sepsis or severe sepsis according to SCCM/ACCP criteria, defined by the present authors as severe active tuberculosis, participated in the study. A low-dose ACTH test with 10 mg of ACTH was performed. After ACTH test, all patients received a stress dose of hydrocortisone (240 mg/day) during their entire hospitalization along with four antituberculous drugs. Abnormal response was considered when elevation of serum cortisol was <7 microg/dl with respect to basal level, 60 min after ACTH administration. RESULTS: Adrenal insufficiency was found in seven patients (39%); no clinical or laboratory data were associated with the presence of abnormal adrenal response. Except in one patient with HIV infection, all the signs and symptoms improved after antituberculous and hydrocortisone treatment. The increment in serum cortisol value post-ACTH test was lower in patients with hypoalbuminemia. CONCLUSIONS: Adrenal insufficiency is frequent in severe active tuberculosis. The efficacy and security of supplemental steroid treatment in severe active tuberculosis should be established by a randomized clinical trial.